Alumis skin disease drug meets main goal of two late-stage trials

Core Insights - Alumis announced that its experimental pill achieved the primary endpoint in two late-stage studies involving patients with a specific type of skin disease [1] Company Summary - The experimental pill developed by Alumis is aimed at treating a type of skin disease and has shown positive results in late-stage clinical trials [1]